Compare NP & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NP | AMRX |
|---|---|---|
| Founded | 2017 | 2002 |
| Country | United States | United States |
| Employees | 60 | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.0B |
| IPO Year | N/A | 2018 |
| Metric | NP | AMRX |
|---|---|---|
| Price | $31.48 | $18.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $28.17 | $15.60 |
| AVG Volume (30 Days) | 936.6K | ★ 2.1M |
| Earning Date | 04-22-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | N/A |
| Revenue This Year | $25.84 | $4.48 |
| Revenue Next Year | $15.80 | $7.13 |
| P/E Ratio | ★ N/A | $94.95 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.78 | $7.67 |
| 52 Week High | $34.61 | $18.08 |
| Indicator | NP | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.42 | 74.46 |
| Support Level | $23.62 | $12.46 |
| Resistance Level | $31.63 | N/A |
| Average True Range (ATR) | 1.53 | 0.55 |
| MACD | -0.24 | -0.04 |
| Stochastic Oscillator | 40.72 | 89.69 |
Neptune Insurance Holdings Inc is a high-growth, profitable, data-driven MGA that offers residential and commercial insurance products, including primary flood insurance, excess flood insurance and parametric earthquake insurance, distributed through a nationwide network of agencies in the United States. The company underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies and does not take any balance sheet insurance risk or have claims handling responsibility relating to the policies it sells.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.